| NDC Number | Brand Name | Generic Name | Manufacturer | Dosage Form | DEA Sch. | Marketing Start Date |
|---|---|---|---|---|---|---|
| 0002-4182 | Olumiant | baricitinib | Eli Lilly and Company | TABLET, FILM COATED | 2018-05-31 | |
| 0002-4479 | Olumiant | baricitinib | Eli Lilly and Company | TABLET, FILM COATED | 2022-05-10 | |
| 0002-4732 | Olumiant | baricitinib | Eli Lilly and Company | TABLET, FILM COATED | 2019-10-08 | |
| 0002-6885 | Baricitinib | baricitinib | Eli Lilly and Company | TABLET, FILM COATED | 2021-12-20 | |
| 0069-0235 | Cibinqo | abrocitinib | Pfizer Laboratories Div Pfizer Inc | TABLET, FILM COATED | 2022-02-24 | |
| 0069-0335 | Cibinqo | abrocitinib | Pfizer Laboratories Div Pfizer Inc | TABLET, FILM COATED | 2022-02-24 | |
| 0069-0435 | Cibinqo | abrocitinib | Pfizer Laboratories Div Pfizer Inc | TABLET, FILM COATED | 2022-02-24 | |
| 0074-1043 | Rinvoq | Upadacitinib | AbbVie Inc. | TABLET, EXTENDED RELEASE | 2019-08-16 | |
| 0074-2306 | Rinvoq | Upadacitinib | AbbVie Inc. | TABLET, EXTENDED RELEASE | 2019-08-16 | |
| 0074-2310 | Rinvoq | Upadacitinib | AbbVie Inc. | TABLET, EXTENDED RELEASE | 2019-08-16 | |
| 0074-2320 | Rinvoq | Upadacitinib | AbbVie Inc. | SOLUTION | 2024-04-26 | |
| 50222-280 | Anzupgo | delgocitinib | LEO Pharma, Inc | CREAM | 2025-07-24 | |
| 50881-005 | JAKAFI | ruxolitinib | Incyte Corporation | TABLET | 2011-11-16 | |
| 50881-010 | JAKAFI | ruxolitinib | Incyte Corporation | TABLET | 2011-11-16 | |
| 50881-015 | JAKAFI | ruxolitinib | Incyte Corporation | TABLET | 2011-11-16 | |
| 50881-020 | JAKAFI | ruxolitinib | Incyte Corporation | TABLET | 2011-11-16 | |
| 50881-025 | JAKAFI | ruxolitinib | Incyte Corporation | TABLET | 2011-11-16 | |
| 63539-236 | CIBINQO | abrocitinib | U.S. Pharmaceuticals | TABLET, FILM COATED | 2022-02-24 | |
| 63539-336 | CIBINQO | abrocitinib | U.S. Pharmaceuticals | TABLET, FILM COATED | 2022-02-24 | |
| 63539-436 | CIBINQO | abrocitinib | U.S. Pharmaceuticals | TABLET, FILM COATED | 2022-02-24 |
Loading full table content...